TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Significant Decline in Short Interest

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 339,800 shares, a decline of 37.2% from the February 28th total of 540,900 shares. Based on an average daily trading volume, of 6,040,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 54.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of TransCode Therapeutics in a research note on Thursday, March 13th.

TransCode Therapeutics Trading Up 1.0 %

Shares of RNAZ stock traded up $0.01 during trading hours on Monday, hitting $0.50. The stock had a trading volume of 4,508,668 shares, compared to its average volume of 1,753,617. TransCode Therapeutics has a one year low of $0.43 and a one year high of $66.33. The stock’s 50-day moving average price is $5.01 and its two-hundred day moving average price is $216.88.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.